Alliancebernstein L.P. Rubius Therapeutics, Inc. Transaction History

Alliancebernstein L.P.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.79 - $5.98 $47,558 - $359,996	-60,200 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$4.25 - $10.4 $850 - $2,080	200 Added 0.33%	60,200 $332,000
Q3 2021 Nov 10, 2021	SELL	$17.6 - $25.91 $54,560 - $80,321	-3,100 Reduced 4.91%	60,000 $1.07 Million
Q2 2021 Jul 30, 2021	BUY	$22.26 - $28.43 $86,814 - $110,877	3,900 Added 6.59%	63,100 $1.54 Million
Q1 2021 May 06, 2021	SELL	$8.02 - $32.01 $150,776 - $601,788	-18,800 Reduced 24.1%	59,200 $1.57 Million
Q4 2020 Feb 08, 2021	SELL	$4.23 - $8.73 $13,536 - $27,936	-3,200 Reduced 3.94%	78,000 $592,000
Q3 2020 Nov 12, 2020	SELL	$4.65 - $6.25 $9,765 - $13,125	-2,100 Reduced 2.52%	81,200 $407,000
Q2 2020 Aug 13, 2020	BUY	$4.01 - $6.88 $56,541 - $97,008	14,100 Added 20.38%	83,300 $498,000
Q1 2020 May 14, 2020	BUY	$3.74 - $9.84 $88,638 - $233,208	23,700 Added 52.09%	69,200 $308,000
Q4 2019 Feb 18, 2020	SELL	$7.23 - $14.12 $20 Million - $39.1 Million	-2,769,072 Reduced 98.38%	45,500 $432,000
Q3 2019 Nov 14, 2019	BUY	$7.85 - $15.75 $2.37 Million - $4.76 Million	302,120 Added 12.02%	2,814,572 $22.1 Million
Q2 2019 Aug 14, 2019	BUY	$13.5 - $19.94 $154,413 - $228,073	11,438 Added 0.46%	2,512,452 $39.5 Million
Q1 2019 May 14, 2019	BUY	$13.27 - $18.51 $2.88 Million - $4.02 Million	216,967 Added 9.5%	2,501,014 $45.3 Million
Q4 2018 Feb 13, 2019	BUY	$13.83 - $22.97 $9.09 Million - $15.1 Million	657,192 Added 40.4%	2,284,047 $36.7 Million
Q3 2018 Nov 08, 2018	BUY	$20.06 - $26.94 $32.6 Million - $43.8 Million	1,626,855 New	1,626,855 $39 Million

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.